The last several years have been a period of extraordinary scientific achievement and cancer research expansion, both at DFCI and within the Harvard medical school community. Although significant progress has been made in the diagnosis and treatment of cancer, this disease continues to represent a major cause of childhood and adult mortality. Important advances in our fundamental understanding of the immune response have suggested new clinical approaches to the diagnosis and treatment of leukemias and solid tumors. Significant advances have occurred in the areas of basic biological science, including tumor suppressor genes, cell cycle regulation, oncogene signaling, cell differentiation, apoptosis control, organogenesis and angiogenesis. Recent advances in targeted cancer therapies, new modalities of cancer cell imaging, and a deeper understanding of genetics and cancer risk highlight the potential of these discoveries to translational research which, in turn, has opened new areas of opportunity for today's young scientists. An essential part of this effort is the training of young scientists in basic and clinical immunology to become independent investigators in cancer immunology. At DFCI, translational research has been an ongoing collaborative effort between faculty in basic and clinical Immunology for many years. Collaboration is increasing between basic and clinical scientists to develop innovative approaches to disease prevention, since the formation of the Dana-Farber/Harvard Cancer Center, a consortium of the affiliated hospitals, which has allowed expansion of our Program Faculty to include distinguished scientists from the entire Harvard Medical School community, all of whom are leading investigators in basic and translational/clinical immunology. Faculty have expanded their research into new areas, including gene silencing, molecular pathogenesis of viruses (a significant cause of cancer, especially in immune-deficient individuals) and tumor biology. In addition, expanded infrastructure and core resources have enhanced access to reagents and provide a more efficient framework in which to carry out research. The program will continue to be directed by Dr. Harvey Cantor who, in conjunction with the Training Program Subcommittee, is responsible for candidate selection, program curriculum, annual review of trainee's research and fostering of interactions among student and faculty members within the Program. The long-range goal of the Program is to train basic scientists to conduct independent high-quality research in cancer immunology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA070083-15
Application #
8288582
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1997-05-05
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$201,852
Indirect Cost
$21,417
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Platzer, Barbara; Elpek, Kutlu G; Cremasco, Viviana et al. (2015) IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Rep :
Leavenworth, Jianmei W; Verbinnen, Bert; Wang, Qin et al. (2015) Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc Natl Acad Sci U S A 112:494-9
Frock, Richard L; Hu, Jiazhi; Meyers, Robin M et al. (2015) Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 33:179-86
Leavenworth, Jianmei W; Verbinnen, Bert; Yin, Jie et al. (2015) A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol 16:96-106
Yin, Jie; Leavenworth, Jianmei W; Li, Yang et al. (2015) Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci U S A 112:15988-93
Elpek, Kutlu G; Cremasco, Viviana; Shen, Hua et al. (2014) The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunol Res 2:655-67
Cremasco, Viviana; Woodruff, Matthew C; Onder, Lucas et al. (2014) B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nat Immunol 15:973-81
Alvarez Arias, Diana A; Kim, Hye-Jung; Zhou, Penghui et al. (2014) Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. Cancer Immunol Res 2:207-16
Kim, Hye-Jung; Cantor, Harvey (2014) CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2:91-8
Leavenworth, Jianmei W; Tang, Xiaolei; Kim, Hye-Jung et al. (2013) Amelioration of arthritis through mobilization of peptide-specific CD8+ regulatory T cells. J Clin Invest 123:1382-9

Showing the most recent 10 out of 37 publications